NCT01664962

Completed

Search for Genetic Basis of Vulvodynia

Western Galilee Hospital-Nahariya Source

Other study identifiers

Sponsor study identifier

920080002

Study Type

observational

Actual enrollment (reported)

168

Locations

1 country

Sites

1

Timeline

Study Start

November 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

January 2012

Actual (reported)

Study Completion

March 2012

Actual (reported)

Brief Summary

The purpose of this study is to investigate the possibility of an association between Localized Provoked Vulvodynia (LPV) that is both severe and primary and polymorphic markers/single nucleotide polymorphisms (SNPs) in and around the genes encoding heparanase (HSPE-1), Vanilloid Receptor VR1 (TRPV1), and Nerve Growth Factor (NGF).

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 168 participants
Study completion date: March 2012
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
November 2008
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
January 2012
Actual (reported)
Study Completion
March 2012
Actual (reported)
First Submitted
August 9, 2012
Actual (reported)
First Posted
August 14, 2012
Actual (reported)

Last Updated: August 14, 2012
Status Verified: August 2012
Last Update Submitted: August 13, 2012

Conditions

Vulvodynia

Outcome Measures

Primary Outcomes (1)

Genetic association of Vulvodynia
the possibility of an association between Localized Provoked Vulvodynia (LPV) that is both severe and primary and polymorphic markers/single nucleotide polymorphisms (SNPs) in and around the genes encoding heparanase (HSPE-1), Vanilloid Receptor VR1 (TRPV1), and Nerve Growth Factor (NGF).
four years

Study Arms (2)

Patients

Women with severe Vulvodynia

Healthy controls

Women without vulvodynia

Eligibility Criteria

Age18 Years - 70 Years

Sexfemale

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients with Vulvodynia, Normal healthy controls

You may qualify if:

diagnosed by a gynecological examination with LPV

Sponsors & Collaborators

Western Galilee Hospital-Nahariya
Governmentlead

Study Sites (1)

Western Galilee Hospital

Nahariya, Israel

MeSH Terms

Conditions

Vulvodynia

Condition Hierarchy (Ancestors)

Vulvar DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Enrollment

168 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER GOV
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

August 9, 2012

First Posted

August 14, 2012

Study Start

November 2008

Date type not reported

This date has not been verified as actual or estimated.

NCT02404961

Women's Health Study: Immunological Factors and Risk of Vulvodynia

Completed

NCT00607490

A Randomized Clinical Trial for Women With Vulvodynia

Not ApplicableCompleted

NCT07391241

A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)

Phase 2Recruiting

NCT07092332

Young Vulvodynia: Effect and Efficacy of Multimodal Treatment.

Not ApplicableActive Not Recruiting

NCT04711369

Lasertherapy for Vulvodynia

Not ApplicableActive Not Recruiting

NCT02733172

Profiling Vulvodynia Based on Neurobiological and Behavioral Endophenotypes

Completed

diagnosed with a severe degree of the syndrome according to Marinoff \[48\]

classified with the primary type of the syndrome according to an interview

with both parents of Ashkenazi origin.

Contact the study team to confirm eligibility.

Primary Completion

January 2012

Actual (reported)

Study Completion

March 2012

Actual (reported)

Last Updated

August 14, 2012

Record last verified: 2012-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01664962
Data provider: ClinicalTrials.gov
Source updated: 2012-08-14
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:28:59 UTC

Locations

IL(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Patients

Healthy controls

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

Source record

Locations